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Synthesis of a-aminoboronic acids
Patricia Andre´s, Gema Ballano, M. Isabel Calaza and Carlos Cativiela*
This review describes available methods for the preparation of a-aminoboronic acids in their racemic
or in their enantiopure form. Both, highly stereoselective syntheses and asymmetric procedures leading
to the stereocontrolled generation of a-aminoboronic acid derivatives are included. The preparation of
acyclic, carbocyclic and azacyclic a-aminoboronic acid derivatives is covered. Within each section, the
diﬀerent synthetic approaches have been classified according to the key bond which is formed to
complete the a-aminoboronic acid skeleton.
1. Introduction
In the last few decades important biomedical applications1 have
been established for compounds containing a-aminoboronic
acids in their structure (Fig. 1). Most developments aimed at the
use of a-aminoboronic acids in the area of protease inhibition.1 In
this context, the discovery of bortezomib (Fig. 1) represented a
very significant advance and it presently constitutes an important
treatment for multiple myeloma and mantle cell lymphoma.
The a-aminoboronic acid residue in bortezomib, L-boroleucine,2
is key for its proteasome-inhibitory activity.3 It forms tetrahedral
adducts with the hydroxyl groups of threonine residues at the
catalytic sites of 20S proteasome that block the enzymatic activity.
Such adducts are considered transition state analogues for
deacylation reactions that occur during proteasome-dependent
proteolysis. The clinical eﬃcacy of bortezomib encouraged further
studies for its optimal delivery to tumours,4 as well as the develop-
ment of new analogues,5 such as orally active ixazomib5a (Ninlaros
has recently been granted approval by FDA) and delanzomib,5b,c
which preserve the key a-aminoboronic residue (Fig. 1).
The analogous mechanism of inhibition in serine proteases
has led to a wide range of compounds with pharmacologically
relevant properties (Fig. 2).1,6–9 Among the targeted enzymes1 are
thrombin, dipeptidyl peptidases (DPPs),6 b-lactamases,7 penicillin-
binding proteins (PBPs), HCV NS3/4A protease, enteropeptidase,
and mycosin-1 protease.8,9 In this context, the most significant
advances have been achieved in the development of compounds
with anticancer, antiviral, and antibacterial activities, which are
in various phases of clinical trials (Fig. 2).
The increasing interest in a-aminoboronic acids is also
linked to their utility as building blocks10 and their potential
use in sensing applications.11 In fact, boroglycine constitutes
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the key recognition part of a fluorescent tracer (Fig. 3) for
binding assays that are aimed at the identification of inhibitors
of PBPs and b-lactamases.11a Besides, boronic acid analogues
of L- and D-1-naphthylalanine,11b and their bisboronic acid
derivatives (Fig. 3),11c are being examined as carbohydrate sensors,
due to their significant fluorescent property changes upon
sugar binding, and their water solubility.
The enormous potential of a-aminoboronic acids has stimu-
lated a great deal of innovation on synthetic methods for their
preparation.12 The diﬃculties associated with their isolation,
which are due to the reactivity of the C–B bond, constitute
a major synthetic issue.12b The electron-deficient nature of the
boron atom in its trivalent form enables it to form a three-
membered ring adduct with the nitrogen atom. Such an adduct
is subsequently protonated at carbon with concomitant C–B
bond cleavage. For this reason, the preparation of suitable
protected a-aminoboronic acid derivatives is assumed.
Herein, we wish to illustrate the progress of synthetic
methods utilized for the construction of a-aminoboronic acid
derivatives. Specifically, the preparation of acyclic, carbocyclic
and azacyclic a-aminoboronic acid derivatives is covered.
Fig. 1 Proteasome inhibitors that contain an a-aminoboronic acid in their
structure.
Fig. 2 Boron-based serine protease inhibitors that exhibit pharmacolo-
gically relevant properties.
Fig. 3 a-Aminoboronic acid-based investigational fluorescent sensors.
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The diﬀerent synthetic approaches, within each section, have
been classified according to the bond which is formed to
complete the a-aminoboronic acid skeleton.
2. Synthesis of acyclic a-aminoboronic
acids
2.1. Formation of the C–B bond
2.1.1. Addition of a-amino organometallic compounds to
boron-containing electrophiles. Synthetic routes towards acyclic
a-aminoboronic acids that involve the borylation of a-amino
metalated species are scarce in the literature.13,14 In 2000, Priestley
and Decicco13 described the preparation of acyclic (Scheme 1) and
carbocyclic (vide infra) a-aminoboronic acid esters by the reaction
of metalated isocyanides with trialkyl borate esters. Regrettably,
the boronic analogue of a-aminoisobutyric acid (3, Scheme 1) was
obtained in very low yield by reaction of the metalated isocyanide
with triisopropyl borate, followed by acid hydrolysis. Such a low
yield was attributed to the instability of the resulting a-isocyano-
boronic ester under basic reaction conditions.
More recently, Srebnik and Shibli14 reported the use of amino-
boranes and aminocyanoboranes (4, Scheme 2) as precursors for the
preparation of a-aminoboronic esters 5. The borane and cyano-
borane groups inductively facilitate the selective a-deprotonation
of the tertiary amines. The resulting lithiated complexes reacted
readily with the boron-containing electrophile and furnished
racemic a-alkylaminoboronic acid esters 5 in good yields.
2.1.2. Addition of nucleophilic boron reagents to imines. By
contrast, nucleophilic borylations15 of imines have emerged as
very eﬃcient approaches for the preparation of highly enantioen-
riched a-aminoboronic acid derivatives. In this context, the stereo-
control has been either achieved by the presence of a chiral
auxiliary at the aldimine, or employing chiral catalysts with
achiral substrates.
2.1.2.1. Substrate-controlled approach. In 2008, Ellman et al.
reported the first stereoselective borylation of chiral sulfinyl-
imines 6 (Scheme 3),16a on the basis of preceding studies of
diboration of racemic N-aryl aldimines.16b Ellman’s procedure
involved in situ generation of a copper(I) boryl complex 7
(Scheme 3) by the treatment of bis(pinacolate)diboron (B2Pin2)
with (1,3-dicyclohexylimidazol-2-ylidene)copper(I) tert-butoxide,
also named as Sadighi’s catalyst. The reaction of the active
catalytic species (7) with sulfinylimines 6 proceeded at room
temperature with good yield and high diastereoselectivity for a
wide range of substrates (Scheme 3). The transformation was also
achieved at 0 1C albeit with higher catalyst loading. The stereo-
selectivity observed was consistent with coordination of 7 from
the least hindered face of the aldimine. Selective removal of the
N-sulfinyl group under acidic conditions enabled the production
of highly enantioenriched a-aminoboronic ester derivatives.
The same catalyst was applied by Li et al. to the asymmetric
borylation of imine 9 that bears a chiral N-phosphinyl auxiliary
(Scheme 4).17 This group anchored onto the aldimine displayed
good asymmetric induction in the borylation reaction and
facilitated the isolation of the desired product by avoiding
conventional purification methods (group-assisted purification
concept). Thus, diastereomerically pure 10 was obtained by washing
the crude reaction mixture with hexanes, and the chiral
N-phosphinyl auxiliary was readily recovered after the subse-
quent deprotection step.
In recent work, the reactivity of copper(I) boryl complexes
supported by diﬀerent N-heterocyclic carbene (NHC) ligands
Scheme 1
Scheme 2
Scheme 3
Scheme 4
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is described.18,19 Benzimidazole-18a and triazine-18b based
N-heterocyclic carbene (NHC) precursors (12 and 13 respectively,
Scheme 5) lead to copper(I) boryl complexes that proved quite
eﬃcient catalysts for borylations of chiral sulfinylimines 6
(Scheme 5, entries 1–8). Remarkably, these reactions took place
in a one-pot procedure without the need of a glove box as it was
required with Sadighi’s catalyst (Scheme 3).16a
In addition to this, Ellman et al.19 developed an air- and
moisture-stable copper(II) catalytic system for the borylation of
6 (Scheme 5, conditions C). It is worth noting that not only
sulfinylimines (Scheme 5, entries 9–12), but also ketimines
(Scheme 6) reacted readily to provide access to a-sulfinamido
boronate esters in good yields and with high stereoselectivities. The
stereocontrol achieved with the catalytic system CuSO4/PCy3HBF4
was shown to be dependent on the nature of the phosphorus
ligand, the ligand to copper ratio and the solvent mixture. It was
found that the use of benzylamine as an additive was not essential
for the phosphine salt selected but it proved beneficial for the
borylation of challenging substrates such as 17 (Scheme 6).
Alternatively, the addition of boron to N-tert-butanesulfinyl
aldimines and ketimines 20 was possible in the absence of a
transition metal complex as a catalyst (Scheme 7).20 In this
procedure, it was the in situ generated methoxide anion which
was responsible to activate the diboron reagent and to promote
the addition in the presence of an N-heterocyclic carbene as a
ligand. The sp2 boron atom in the adduct gains a nucleophilic
character whereas the one that interacts with methoxide anion
loses electron density because of the lack of electron donation
from the oxygen atoms of its pinacolate moiety.21 Specifically, the
use of carbene precursor 12 (Scheme 5), with a benzimidazole
core, allowed the reaction to be performed without requiring an
inert atmosphere.
2.1.2.2. Reagent-controlled approach. The first catalytic enantio-
selective approach for the synthesis of a-aminoboronic esters was
reported by Ferna´ndez et al., who conducted nucleophilic boron
addition to tosylaldimines 22 in the presence of chiral phosphines
as ligands (Scheme 8).22 The use of such phosphines proved
to be essential for enantiofacial diﬀerentiation in the course of
the reaction, even though aliphatic tosylaldimines gave low
enantioselectivities (entries 7 and 8).
Later, enantioselective copper-catalyzed boryl additions to
N-benzoyl23 and N-tert-butoxycarbonyl (N-Boc)10e aldimines were
accomplished (Scheme 9). On one hand, the asymmetric addition
of B2Pin2 to N-benzoyl aldimines (entry 1) involved the use of
NHC–Cu complexes in situ-generated by the treatment of 27 with
sodium tert-butoxide and copper chloride.23 The reaction proceed
smoothly and gave excellent yields and high enantioselectivities for
a broad scope of 4-substituted benzaldimines regardless of their
electronic nature. However, some erosion in enantioselectivity was
observed for sterically hindered 2- or 3-substituted benzaldimines.
Alkyl aldimines were also effective under the reaction conditions
but they were generated in situ by the treatment of a-tosylamine
precursors with a base, in order to avoid their decomposition.
On the other hand, Liao et al.10e reported a highly enantio-
selective copper(I)-catalyzed boryl addition to N-Boc aldimines
Scheme 5
Scheme 6
Scheme 7
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(Scheme 9, entries 2 and 3) by using chiral sulfoxide-
dialkylphosphine 28 as a ligand. Remarkably, both enantio-
mers of a-aminoboronic esters 29 were obtained through a
counteranion switch in the cationic copper(I) catalyst that was
in situ-generated. The boryl copper species generated from
precatalyst 28-Cu-OtBu underwent addition from the Si-face
of the imine and aﬀorded the (S)-products (entry 2). Conversely,
the cationic copper complex with a larger anion, (28-Cu)+ BARF,
induced the opposite absolute configuration of 29 (entry 3).
It was reasoned by the authors that the pinacolboryl moiety
approaches the cationic copper complex from the back side of
the BARF anion. As a consequence of this, the boryl-copper
species underwent addition from the Re-face of the imine
due to its coordination trans to the tert-butylsulfinyl group.
The reaction gave high enantioselectivities for a broad scope of
benzaldimines. Only low enantioselectivities were observed for
ortho-substituted aryl aldimines when NaBARF was used as an
additive and for alkyl aldimines with both catalytic systems.
In a related work, Morken and Hong24 showed the diboration
of in situ-generated silyl imines with B2Pin2 in the presence of a
Pt–phosphonite catalyst made, in turn, from 32 (Scheme 10). The
resulting diboration adducts 33 were directly acylated, thus
providing straightforward access to N-acyl a-aminoboronic esters
34 or peptide derivatives such as 35.
2.1.3. Hydroboration of enamides. It is only very recently
that Tang et al. described the first enantioselective synthesis of
a-amino tertiary boronic esters by rhodium-catalyzed hydro-
boration of a-arylenamides (Scheme 11).10d The treatment of
the latter with B2Pin2 in the presence of a rhodium complex,
generated from phosphorous-chiral ligand 37, yielded a-amino-
boronic esters 38 in good yields and excellent enantioselectivities.
The regiocontrol achieved was shown to be due to the presence
of a carbonyl directing group in the starting substrates.
Scheme 8
Scheme 9
Scheme 10
Scheme 11
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Under optimized conditions of solvent, base and ligand, the
hydroboration was broad in scope, particularly regarding the
electronic properties and the substitution pattern of the aryl group
(Ar) in 36. Experimental studies supported the hydroboration
reaction pathway and allowed to discard the tautomerization of
36 followed by diboration of the resultant acyl imine as an
alternative mechanism. The catalytic cycle of the hydroboration
involved oxidative addition of bis(pinacolate)diboron to the
rhodium complex, reaction with the N–H of 36 to yield boryl
rhodium hydride species, olefin insertion to the Rh–H bond,
and reductive elimination.
2.1.4. C(sp3)–H borylation reactions. The direct C(sp3)–H
borylation a to a N atom certainly is a straightforward approach
for synthesizing a-aminoboronic acid derivatives (Scheme 12).
This type of C–B bond assembly has been recently achieved by
using a diboron reagent in the presence of different hetero-
geneous catalytic systems.25 The combination of [Rh(OMe)(cod)]2
with silica-supported triarylphosphanes (A and B, Scheme 12) gave
mono(phosphane)–metal complexes that enabled the selective
borylation of N-adjacent C(sp3)–H bonds of amides and ureas 39
under quite mild reaction conditions.25a,c According to the authors,
the tryptycene-type cage structure featured by triarylphosphanes
A and B and their immobilization proved critical factors for
borylation activity. Such structural features resulted in an efficient
isolation of each phosphane center, thus allowing the selective
1 : 1 metal-phosphane coordination.
Furthermore, Sawamura et al.25b described the catalytic appli-
cation of a polystyrene-phosphane covalently bound hybrid
(C, Scheme 12) for Rh-catalyzed N-adjacent C(sp3)–H borylations.
In this case, the three-fold cross-linking increases the density of
the polymer around the phosphane core, thus achieving 1 : 1
metal-phosphane ligation, and generates a ligand steric effect
moderate enough to ensure catalytic performance.
These procedures gave access to boroglycine and boro-
phenylglycine derivatives (Scheme 12) in good yields based on
boron. The required excess of substrate against the boron
reagent constitutes an undesirable feature if the activation of
more laborious substrates is pursued. However, the applicability
of the methodology for the preparation of additional acyclic
a-aminoboronic acid derivatives has not yet been explored.
2.2. Formation of the C–N bond
2.2.1. SN2-like nucleophilic displacements. A great deal of
research has been devoted to the preparation of a-aminoboronic
acid derivatives by reaction of (a-haloalkyl)boronic esters with
nitrogen-based nucleophiles. This strategy was initiated by
Matteson for the synthesis of a-aminomethylboronic esters
(boroglycinates)26 and further developed for the preparation
of a-alkyl, a-alkenyl, and a-arylaminoboronic acid derivatives in
racemic or enantioenriched form (Scheme 13).12e,27
The displacement of iodide from a-iodomethylboronate ester
41 by nitrogen-based nucleophiles was first reported in 1968
(Scheme 14).26 Secondary amines reacted readily with 41 and
furnished a-aminoboronic acids that were isolated as catechol
ester derivatives. In addition, deprotonated amides provided
compounds such as phthalimidomethaneboronic acid 43.
Besides, tertiary amines28 and lithiohexamethyldisilazane29–31
reacted with a-halomethylboronic esters 44 and produced stable
quaternary ammonium boronate salts 45 and silylated amino-
boronic esters 46, respectively (Scheme 15). The latter were used as
intermediates for the preparation of formamido-,29 acylamino-,30
and sulfonamidemethylboronic esters.31
More recently, nucleophilic substitutions of a-halomethyl-
boronic esters equipped with a tetracoordinated boron center
have been described (Scheme 16).32 According to the authors,
substitutions of trifluoroborate 51 by alkylamines follow a pure
Scheme 12
Scheme 13
Scheme 14
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SN2 mechanism.
32a By contrast, the nucleophilic displacement
of the halide in a substrate with sp2 hybridization at the boron
atom involves the generation of an intermediate ‘‘ate’’ complex
that undergoes migration of the nitrogen to the neighboring
carbon atom (Scheme 17).12e,27
The mechanism via an ‘‘ate’’-type intermediate is at the base
of Matteson’s homologation methodology (Scheme 17), which
involves the one-carbon chain extension of a sp2-boronic ester.12e,27
Such a procedure has been a standard method for the synthesis
of racemic12e,27,33,34 and enantioenriched a-alkyl-, a-alkenyl-
and a-arylaminoboronic acid derivatives.7a,10a,11c,12e,27,33,35
Specifically, addition of (dichloromethyl)lithium to a pinane-
diol boronic ester 55 (Scheme 17) places the group on the less
hindered face of the chiral director. Rearrangement of the
resulting ‘‘ate’’-complex produces (a-chloroalkyl)boronic ester
56 in high diastereomeric purity.12e Subsequent treatment of 56
with lithiohexamethyldisilazane furnishes the N-silylated deri-
vative with inversion of the configuration. The experimental
conditions for this chain-extending process have been opti-
mized.36 It was found that the presence of zinc chloride in the
mixture enhances the stereoselectivity attained during the
migration step (generally formed inB90–95% if the only cation
is lithium and Z99% if zinc chloride is used).12e,36 This effect
was attributed to the ability of the Lewis acid to act as a
promoter of the rearrangement and as a scavenger of the
chlorine ion that might cause epimerization at the a-carbon
of 56. In addition, the use of diethyl ether as a solvent, instead
of tetrahydrofuran, ensured reproducibility on a large-scale
manufacturing process.36
As already mentioned, the isolation of N-silylated deriva-
tives is usually eluded and N-acyl (Scheme 18, entries 1–6),
N-sulfonyl (Scheme 18, entry 14), and a-aminoboronic esters
bearing tertiary amino groups (Scheme 18, entries 7–13) are
produced.7a,10a,11c,12e,27,33,35 Alternatively, bis(trimethylsilyl)-
amino boronic esters 57 (Scheme 17) have been desilylated
and reacted immediately for the preparation of peptidyl deri-
vatives.37 Mattesson’s homologation proceeded with high dia-
stereoselectivity for a broad scope of pinanediol boronic esters
55 (Scheme 18), generated, in turn, from aryl- and alkyl-
Grignard reagents. Among others, the process gave access to
Scheme 15
Scheme 16
Scheme 17 Scheme 18
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boroalanine, boroleucine, borovaline, borophenylalanine and
boroserine derivatives.
Interestingly, (a-azidoalkyl)-7a,38 (entry 6, Scheme 18) and
(a-hydroxyalkyl)amino boronic esters35m,39 (Scheme 19) proved
useful intermediates for the preparation of bioactive molecules,
such as a-(triazolyl)amino boronic acids,7a a-amino cyclic boronates
60,35m and a-(2-thiazolidinyl)amino boronic acids 63.39
In addition to aryl- and alkylboronic esters, Mattesson’s
homologation has been applied to a-alkenylboronic esters34b,40
such as 6440 (Scheme 20). Subsequent desilylation and acylation
gave a-(acetamido)allylboronate 65 that, in turn, underwent radical
addition of methanethiol to give boromethionine derivative 66.
On the other hand, the hydroboration of allyl bromide furn-
ished an haloalkyl-substituted boronate that proved a convenient
precursor for azidoalkyl-substituted 67 (Scheme 21).41,42 This
substrate gave access to boroornithine41a and boroarginine41b
derivatives when subjected to Matteson’s homologation.
Interestingly, the preparation of boroarginine- and borolysine-
containing peptides42 has often involved the incorporation of
a haloalkyl-substituted a-aminoboronic acid precursor in the
peptide chain, followed by the side-chain transformations
needed. Due to their utility as synthetic intermediates, a few
haloalkyl-substituted a-aminoboronic esters have been isolated
in diastereomerically pure form by transesterification of racemic
precursors 70 with chiral pinanediols under selective crystallization
conditions (Scheme 22).43
The synthetic versatility of chiral (a-haloalkyl)boronic esters
(56, Scheme 17) stimulated the development of additional
methods for their preparation.12e,44–46 The preparative path-
ways include the reaction of dichloromethylboronic esters
of C2-symmetrical chiral diols with organometallic reagents
(Scheme 23),12e,45 and enantioselective hydrogenations of
1-chloro-1-alkenylboronic esters (Scheme 24).46 Matteson reported
the use of dichloromethylboronic esters of C2 symmetric diols
for chiral induction in the synthesis of (a-chloroalkyl)boronic
esters.12e,44 This methodology was applied by Mantri et al. to
the preparation of 74 (Scheme 23), which is a precursor of
boroornithine.45 A high asymmetric induction (499% dr) was
achieved during the reaction of 72 with the dioxolane Grignard
at a reaction temperature readily practicable for large scale synthesis.
The resulting compound was transesterified to pinanediol ester
due to good stability for projected boropeptide chemistry. The
treatment of (a-chloroalkyl)boronic ester 73 with lithium
Scheme 19
Scheme 20
Scheme 21
Scheme 22
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bis(trimethylsilyl)amide (LHMDS) produced an amine that
underwent deprotection in dry ethereal hydrogen chloride
solution to generate hydrochloride salt 74. It should be noted
that pinanediol (dichloromethyl)boronate was also used as a
means of expanding the variety of side-chains to be incorpo-
rated during the synthesis of (a-chloroalkyl)boronic esters.47
However, the resulting diastereomeric ‘‘ate’’-complexes show
quite different levels of stereocontrol during the subsequent
migration step, thus leading to poor diastereomeric ratios of
(a-chloroalkyl)boronic esters.12e
The route towards (a-chloroalkyl)boronic esters 78 (Scheme 24)
based on the asymmetric catalytic hydrogenation of 1-chloro-1-
alkenylboronates 76 was reported by Cˇasar et al. in 2012.46a,b A
range of substrates 76were hydrogenated in the presence of a P^N
ligand-based iridium catalyst. The stereoelectronic features of the
chiral ligand and the substrate concentration were found to have a
significant influence in the reaction outcome. Under optimized
conditions, the transformation occurred without significant deha-
logenation for all substrates. Excellent conversions and good
enantioselectivities were obtained, albeit higher catalyst loadings
were required to achieve full conversions for substrates bearing
bulky alkyl moieties or aryl substituents. In a later report, the
same authors found that 1-bromo-1-alkenylboronic appear to be
less reactive towards hydrogenation with a number of iridium–
P^N complexes.46c In spite of this, the study demonstrated that
high chemoselectivities and enantioselectivities of up to 73% ee,
along with full conversions could be obtained for hydrogena-
tion of acyclic alkyl substituted derivatives.
In addition to the aforementioned methods, a few strategies
that provide access to racemic (a-haloalkyl)boronic esters have
been reported.48–50 Methods available include chlorination
of a-alkoxyboronic esters generated, in turn, by borylation
of a-alkoxyorganolithium reagents,48 cleavage of a carbon–
zirconium bond in boron–zirconium gem-bimetallic species
with N-halosuccinimides (vide infra),49 and the preparation of
(a-haloalkyl)boronic esters under conditions amenable to the
introduction of side chains as electrophiles (Scheme 25).50 In
the latter case, alkyl bromides and methyl acrylate were allowed to
react with the stabilized anion of (phenylthio)methylboronate 80.
The resulting (a-phenylthioalkyl)boronic esters 81 were converted to
the corresponding sulfonium salts by alkylation with excess methyl
iodide. Such salts in the presence of sodium iodide produced a-iodo
derivatives 82. The latter gave access to a-aminoboronic esters 83 by
conventionalmethods. In some cases racemic pinacol boronic esters
were transesterified to (+)-pinanediol esters, and enantiomerically
pure isomers could be separated by chromatography. This strategy
proved particularly valuable with side chains that contain function-
alities which are sensitive to basic conditions, thus being comple-
mentary to those procedures that involve the use of Grignard
reagents. Among others, the methodology provided access to the
boronic analogues of aspartic and glutamic acid.
2.2.2. Allylic aminations. In 2009 Carboni et al. studied
Mitsunobu reactions of (3-hydroxy-buten-1-yl)boronic acid ester
84 with various nucleophiles, and found that the boronic ester
moiety governed the regio- and stereochemical course of the
amination.51 Specifically, the use of N-tosylpropargylamine as the
nucleophile gave access to a-aminoboronic ester 85 (Scheme 26).
On the basis of the regio- and stereoselectivity observed a
plausible reaction mechanism was proposed. It involved
in situ generation of the leaving group, as in the classical
Mitsunobu reaction, the formation of a borate by addition of
the nucleophile to the boron atom, and 1,2-migration of the
nitrogenated group in an SN20 manner. The formation of a
single isomer (E) was rationalized through a transition state
that places the migrating substituent in anti to the leaving
group and arranges for the least possible allylic 1,3-strain.
Scheme 23
Scheme 24
Scheme 25
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The allylic amination of alkenylboronic esters 86 catalyzed
by chiral iridium complexes was later investigated by the same
group (Scheme 27).52 In this case, the nature of the boronic
ester directed the regioselectivity of the process. The use of
trifluoroborates 86 led to a-aminoboronate 87 as the only
product, while pinacol boronic esters preferentially gave the
linear allylic amine. The inversion of regioselectivity was attrib-
uted to the electronic eﬀect of the trifluoroborate group on
the (p-allyl)Ir intermediate. Under optimized conditions of the
solvent and base, the allylic amination was broad in scope for
cyclic amines, but only suited to acyclic amines endowed with a
small cone angle, such as benzylethylamine. Unfortunately, no
data were provided by the authors regarding the enantiomeric
excess of allylic substitution products due to the lack of a
suitable analytical method.
2.2.3. Electrophilic aminations. Sbrenik and Zheng49 reported
the preparation of a-aminoboronic ester 90, in the racemic form, by
electrophilic amination of boron–zirconium gem-bimetallic species
89 (Scheme 28). This species was generated through the regio-
selective hydrozirconation of alkenylboronic ester 88 by using
Schwartz’s reagent. Subsequent selective cleavage of the carbon–
zirconium bond with O-mesitylsulfonyl hydroxylamine (MSH)53
as the electrophilic aminating reagent provided a-aminoboronic
ester 90 in a reasonable yield.
2.2.4. [3,3]-Sigmatropic rearrangements. Pietruszka et al.54
investigated [3,3]-sigmatropic rearrangements of trichloro- and
trifluoroacetimidates 91 as an entry to enantiopure a-amino-
boronic acid derivatives 92 (Scheme 29). However, it was found
that the rearrangement required a very high temperature to
occur and led to 92 as mixtures of diastereoisomers that were
determined to be close to 60 : 40 in all cases. Unfortunately, the
separation of diastereoisomers was unsuccessful and, there-
fore, no further attempts to pursue the approach were made by
the authors.
More recently, Carboni’s group carried out the synthesis of
allylic a-aminoboronic esters 96 via a [3,3]-sigmatropic cyanate–
isocyanate rearrangement of racemic carbamate 93 (Scheme 30).55
Dehydration of 93 with triphenylphosphine, carbon tetra-
bromide and triethylamine gave cyanate 94, which underwent
[3,3]-sigmatropic rearrangement at room temperature. The
resulting allyl isocyanate 95 was transformed in situ by reaction
with a variety of nucleophiles. It was suggested that the rearrange-
ment occurs through a cyclic transition state of six centers with
the boronate and methyl groups in pseudoequatorial positions,
which helps to explain the detection of a single geometric isomer
of E configuration.
Scheme 26
Scheme 27
Scheme 28
Scheme 29
Scheme 30
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2.2.5. Curtius rearrangement of a-borylcarboxylic acids.
Yudin et al. reported an attractive boroalkyl group migration that
provides access to a-aminoboronic acid derivatives (Scheme 31).56
The procedure56a,b involved the preparation of a-borylisocyanates
98 via Curtius rearrangement of a-borylcarboxylic acids 97.57 The
thermal decomposition of the intermediate carboxylic azides
worked well with aryl- or alkyl-substituted precursors (entries 1–7)
and with a,a-disubstituted analogues (entry 8). In addition,
a-borylcarboxylic acid 100 was used for the stereochemical
investigation of the migratory process that it was found to occur
with complete retention of the configuration. The resulting
a-borylisocyanates 98 have enabled the synthesis of a-amino-
boronic acid derivatives 99 by reaction with amine and alcohol
nucleophiles at the isocyanate group.
In addition, the deoxygenation of isocyanates 102 (Scheme 32)
furnished isocyanides 103 that enabled the preparation of boro-
peptides through a multicomponent approach.56c
3. Synthesis of carbocyclic
a-aminoboronic acids
As mentioned in Section 2.1.1, Priestley and Decicco13 reported
the preparation of carbocyclic a-aminoboronic acid esters
through borylation of a-amino metalated species. Specifically,
three- and six-membered carbocyclic a-aminoboronates 107
(Scheme 33) were obtained through a three-step sequence that
involved the addition of metalated isocyanides to triisopropyl
borate, esterification of the boronic acids isolated after the hydro-
lytic work-up, and acid-catalyzed hydrolysis of isocyanides 106.
4. Synthesis of azacyclic
a-aminoboronic acids
4.1. Formation of the C–B bond
4.1.1. Addition of a-amino organometallic compounds to
boron-containing electrophiles. The ease of the lithiation of
N-Boc-pyrrolidine 108 has been applied to the preparation of
boroproline both in racemic58 and enantioenriched forms59
(Scheme 34). Treatment of 108 with sec-butyllithium in the
presence of tetramethylethylenediamine (TMEDA) generated
a-anionic species that eﬃciently reacted with trimethyl borate.58a
The resulting boroprolinate was hydrolysed during the work-up
to give 109 in high yield. Diastereochemically pure 111a was
Scheme 31
Scheme 32
Scheme 33
Scheme 34
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produced through a sequence60 that involved esterification of
the racemic precursor 109 with (+)-pinanediol, deprotection of the
amine functionality under acidic conditions, and sequential
selective crystallizations of the resulting amine hydrochloride
(Scheme 34). The absolute configuration of the new stereogenic
center was assigned as R on the basis of X-ray diﬀraction analysis
of 111a. Scale-up of the overall process engaged several modifica-
tions for the a-metalation step, such as avoidance of TMEDA as an
additive, and improvements for recycling the chiral auxiliary that
is employed as a resolving agent.58b
Alternatively, highly enantioselective syntheses of N-Boc
protected boroproline have been accomplished by asymmetric
directed a-metalations of 108 (Scheme 34).59 Specifically,
()-sparteine-mediated lithiation of 108 and subsequent treat-
ment with triisopropyl borate yielded (S)-configured boroproline
109b with 90% ee.59a In contrast, the use of diamine 112 for
the generation of the chiral lithium–carbanion pair furnished
(R)-configured boroproline 109a with 95% ee.59b
More recently, Lai et al. described the preparation of the cis
stereoisomer of 4-hydroxy-l-boroproline 115 (Scheme 35) for
designing dipeptidyl peptidase IV inhibitors for the treatment
of type II diabetes.61 The lithiation of pyrrolidinol 113 required
the use of an additional equivalent of sec-butyllithium and to raise
the temperature to 46 1C for two hours. After treatment with
triisopropyl borate and hydrolytic work-up the crude mixture was
esterified with (+)-pinanediol. Diastereochemically pure 115 was
isolated in 35% yield by crystallization of the diastereoisomeric
mixture. The stereochemistry and regiochemistry of the process
were unambiguously assigned by 2D NMR of cyclic dipeptide
derivatives.
4.1.2. C(sp3)–H borylation reactions. Rh-catalyzed N-adjacent
C(sp3)–H borylation through heterogeneous approaches were also
applicable to the preparation of racemic a-aminoboronic ester
derivatives with azacyclic structure (Scheme 36).25 The catalytic
species generated from silica-supported phosphane ligands25a,c
enabled the selective borylation of amides and ureas 116 (entries 1
and 2, respectively) under mild reaction conditions. The selectivity
for ring borylation was not limited to the use of N-acyl groups
as catalyst directing groups, but also to N-heterocyclic groups. In
fact, pyridine worked well as a directing group for catalysts
generated from silica-,25a,c or polystyrene-supported25b phosphane
ligands and azacyclic a-aminoboronic esters were obtained from
saturated cyclic amines with different ring sizes (entries 3–7).
4.2. Formation of the C–N bond
4.2.1. Two-component cyclizations. In 2011, Walsh et al.
reported the synthesis of boron-substituted aziridines 119 by
the treatment of BPin-substituted allylic alcohols 118 with
N-aminophthalimide as the nitrogen source in the presence
of di(acetoxyiodo)benzene (Scheme 37).62 The nitrene, which is
generated by the action of this oxidant, produced BPin-
substituted aziridines 119 in good yields with high levels of
diastereoselectivity. The nature of the solvent, the presence of a
base, and the order of addition of reagents were found to have a
significant influence on the reaction outcome. The syn relative
stereochemistry between the aziridine ring and the hydroxyl
group was confirmed by X-ray diﬀraction analysis of 119 (R1 = iPr,
R2 = 4-MeO-Ph). The chemoselectivity attained with dyene 120
Scheme 35
Scheme 36
Scheme 37
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suggested the reactions being accelerated and directed by the
allylic hydroxyl group.
4.2.2. Intramolecular C–N cyclization. In 1990, the procedure
developed by Matteson for the synthesis of a-aminoboronic acids
was applied to the synthesis of racemic boroproline derivatives
(Scheme 38).63 The pyrrolidine ring was assembled by intra-
molecular C–N cyclization of a halogen-substituted a-amino-
boronic ester. The latter was obtained by the treatment of 122
with LHMDS. The cyclization reaction took place by distillation
of the crude N-silylated a-aminoboronic ester intermediate.
This type of chain-extension methodology was later applied
by Matteson and Lu to the asymmetric synthesis of 131, which
is an analogue of kainic acid having cyano and boronic acid
moieties in place of the two carboxylic acid groups (Scheme 39).64
The cyanomethyl and bis(trimethylsilyl)amino substituents were
sequentially incorporated into pinanediol boronate 125. Accord-
ing to the authors, all of the boronic ester intermediates were
produced in high diastereomeric purity, with the exception of 126.
In this case, reaction of 125 with (dichloromethyl)lithium gave
better yield when conducted without zinc chloride. The major
isomer of the diastereomeric mixture (drB 10 : 1) was obtained
by crystallization. The deprotection of the oxygen group in 128
involved the generation of a formate ester that was subse-
quently treated with potassium thiocyanate. The resulting
hydroxyl group was mesylated under standard conditions.
The pyrrolidine ring formation took place rapidly by the treat-
ment of 129 with lithium diisopropylamide.
More recently, Sun et al. reported18b the asymmetric synthesis
of 14h by copper(I)-catalyzed borylation of a chiral sulfinylimine
precursor (Section 2.1.2.1, Scheme 5). The tolerance of this
methodology to the presence of a chloride group in the starting
sulfinylimine was further exploited for the preparation of the
cyclic derivative (Scheme 40). Thus, the treatment of 14h with
base led to intramolecular cyclization and gave 132 in high
diastereomeric purity. Removal of the N-protecting group gave
boroproline ester 111a.
4.3. Intramolecular C–C bond formation
4.3.1. Ring-closing metathesis. In 2004, Carboni et al.
reported ruthenium catalyzed ring-closing metathesis as the
key step for the synthesis of cyclic a-aminoboronic esters 134,
in racemic form (Scheme 41).65 The Grubbs catalyst was found
to be eﬀective for six- and seven-membered ring formation
from N-Boc- or N-tosylaminoboronates 133 (entries 2–5). In
addition, substrates with 1,1-disubstituted double bonds gave
moderate yields of cyclic a-aminoboronic esters, such as 134f,
in the presence of second-generation Grubbs catalysts. Instead,
five-membered ring-closing proved difficult due to the instability
of the products in the presence of either catalyst, and only a
moderate yield of 134a (entry 1) was obtained with catalyst C.
Deprotection and hydrogenation of the double bond in 134b
gave access to the boronic acid analogue of pipecolic acid.
4.3.2. Tandem carbene addition/cyclopropanation. The
same group66 explored the preparation of strained bicyclic
Scheme 38
Scheme 39
Scheme 40
Scheme 41
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a-aminoboronic esters by reaction of 1,6- and 1,7-enynes 85
and 137 (Scheme 42) with trimethylsilyldiazomethane in the
presence of a ruthenium catalyst. The carbene addition/cyclo-
propanation sequence took place under mild conditions and
furnished racemic 136 and 138 in good yields. The major
isomer exhibited a cis configuration of the vinyl and ester group
along with high Z-stereoselectivity for the created alkenyl chain.
4.4. Synthesis from aromatic heterocycles
In 1993, Kelly et al. reported an eﬃcient route for the preparation
of multigram quantities of racemic N-Boc protected boroproline
109 (Scheme 43), that was resolved as previously described
(Scheme 34 in Section 4.1.1).60 The synthetic procedure involved
the lithiation–borylation–reduction of N-Boc protected pyrrole
139.58a,60,67 Treatment of the latter with lithium tetramethylpi-
peridide (LTMP) generated the a-anion that reacted with triethyl-
borate. Hydrolytic work-up produced free boronic acid 140 that
was readily hydrogenated by using Pt/C as a catalyst.
5. Concluding remarks
In this review we have tried to provide a general perspective of
methodologies for the preparation of a-aminoboronic acid
derivatives in either racemic or enantiopure form. A variety of
valuable protocols have been established depending upon
the acyclic, carbocyclic and azacyclic nature of the targeted
structures. Among the implemented methods, the most widely-
applied for the preparation of acyclic a-aminoboronic acids,
Matteson’s methodology, relied on the highly stereoselective
chain-extension of a chiral boronic ester, followed by the
addition of a nitrogen-nucleophile to the electrophilic boron
atom, and stereospecific 1,2-migration of the amino function.
This methodology, wherein the selection of the chiral director sets
up the final stereochemistry, gave eﬃcient access to a broad scope
of highly enantioenriched a-aminoboronic acids. More recently,
nucleophilic borylations of aldimines and rearrangements of
chiral boronates of a-borylcarboxylic acids have delivered note-
worthy contributions for the preparation of this type of com-
pounds. On the other hand, the preparation of azacyclic
analogues has largely addressed the isolation of boroproline
in enantiomerically pure form, as it is part of serine protease
inhibitors with important pharmacological properties. Best
results were accomplished through highly enantioselective
lithiation–borylation of a pyrrolidine precursor, intramolecular
cyclization of a-aminoboronic esters generated by borylation of
a chiral aldimine, and chemical resolution processes.
There is no doubt that the results achieved will encourage
further investigations focusing on the refinement of the pro-
cesses in an eﬀort to improve the enantiomeric purity of the
resulting a-aminoboronic acids. In some cases, the optical
purity and absolute configuration of the final compound has
not been established largely due to the limitations for their
separation and analysis.
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